| ABSTRACT Objective:To evaluate systematically the clinical efficacy and safety of Huangqi injection in treatment of cerebral infarction.Methods:Two researchers searched and selected independently the randomized controlled trials (RCTs) regarding Huangqi injection in the treatment of cerebral infarction in CNKI, VIP, Wanfang Database, PubMed, the Cochrane library and so on by October 2016. Quality of included RCTs was evaluated by The Cochrane Risk of Bias Assessment Tool, and then the required information was extracted and meta analyzed by RevMan 5.3 software.Results:A total of 11 RCTs involving 1 031 patients were included, 556 cases in experiment group and 475 cases in control group. There were 662 male patients and 369 female patients. The result of meta analyzed indicated that Huangqi injection group can achieve a better effect than the routine western medicine group in respect of total effective rate (RR=1.20, 95%CI: 1.14 1.27, P<0.000 01). In addition, it could decrease the whole blood high shear viscosity (MD=-0.65, 95%CI: -1.24 -0.05, P=0.03), whole blood low shear viscosity (MD=-0.87, 95%CI: -1.68 -0.07, P=0.03), and achieve a better effect in the degree of neurological impairment (MD=-6.41, 95%CI: -8.06 -4.76, P＜0.000 01). 3 articles cleared that there was no ADRs in the studies, 1 study reported 3 cases of ADRs. ADRs were all in the experimental group, but there were no serious happened adverse effects. Conclusion:Huangqi injection is effective in treating cerebral infarction. However, these results should be carefully interpreted due to the low methodology quality and small sample size of trials, the evidence of Huangqi injection for treating cerebral infarction requires large scale and double blind RCTs to substantiate these findings. |
